New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2012
18:16 EDTIBM, HPQ, BRK.A, AA, GOOG, WFC, BAC, AAPLApple and Google are the leading candidates to enter the DJIA, Barron's reports
The Dow Jones Industrial Average, or DJIA, hasn't adjusted its component companies since 2009 and is overdue for a makeover, Barron's reports. Since that time, Apple (AAPL) has emerged as the world's most valuable company, with a market value of $570B. Also not on the DJIA list is online advertising-and-search behemoth Google (GOOG). Both represent major shifts in the global business landscape in ways that current Dow components such as Hewlett-Packard (HPQ), Bank of America (BAC) and Alcoa (AA) do not. Yet admitting Apple or Google -- or any other high-priced stock -- would be difficult, given the way the index is calculated based on the absolute price of their shares. With a price of around $605, Apple's shares would overwhelm the index with a 26% weighting. That is double the influence of current Dow component International Business Machines (IBM), whose $207 stock price gives it a 12% weight in the index. Given its big daily swings, Apple alone could move the Dow regularly by 100 points or more. As for Google, it is planning a stock split that would cut its share price in half, to about $300. But even at that level, it would have a hefty 15% weighting in the average. One solution would be to adjust the way the Dow is calculated. Other potential index additions include Berkshire Hathaway (BRKA) and Wells Fargo (WFC), which pose no problem under the current calculation system. Reference Link
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
18:31 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for OPDIVO
Subscribe for More Information
15:23 EDTADako announces FDA approval of new lung test for cancer patients
Subscribe for More Information
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use